Clinical Trial Update: A Clinical Study of Dihydroergotine Mesylate Extended-release Tablets for the Treatment of Drooling in Parkinson's Disease. [Phase 4]

View source ↗

Summary

A Phase 4 clinical study evaluating dihydroergotine mesylate extended-release tablets for reducing drooling in Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Dihydroergotine Mesylate Extended-Release Tablets (dihydroergotine mesylate)

Snippet

Sponsor: Second Affiliated Hospital of Soochow University | Conditions: Salivation in Parkinson's Disease | Phase 4 | Status: COMPLETED